Back to School: How biopharma can reboot drug development. Access exclusive analysis here
DNDN was up $1.34 (20%) to $8.19 on 7.4 million shares on Wednesday on news that it received a Special
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury